Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
BioRestorative Therapies invites investors to attend its presentation at the Emerging Growth Conference on June 9, 2021, at 10:45 AM Eastern Time. The event allows interaction with CEO Lance Alstodt and VP of R&D Francisco Silva. Attendees can ask questions, and a recording will be available post-event. BioRestorative focuses on stem cell therapies, with its leading product BRTX-100 targeting chronic lower back pain. The conference serves as a platform for public companies to present innovative solutions to investors.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the expansion of its Melville, NY research labs for clinical production of cell therapies.
The new cGMP facility will support the Phase 2 clinical trial for BRTX-100 and the ThermoStem® program, enhancing internal manufacturing capabilities.
As part of this initiative, the company plans to hire more employees, aligning operations with FDA and EMA regulations for clinical-grade cell production.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the filing of its Annual Report on Form 10-K for 2020, achieving compliance with SEC requirements. This filing removed the 'stop sign' from its OTC profile, indicating current public information availability. CEO Lance Alstodt expressed optimism regarding the company's positioning for funding opportunities for its phase 2 clinical trial and advances in its metabolics program. The company emphasizes a focus on clinical programs to drive future value for shareholders.
BioRestorative Therapies (OTC: BRTX) announced the appointment of Dr. Nickolay V. Kukekov to its Board of Directors, effective March 18, 2021. Dr. Kukekov brings extensive experience in the Emerging Growth Lifesciences sector and capital markets, focusing on biotech company growth. His appointment is seen as pivotal for pursuing strategic objectives, including capital raising for the Phase 2 clinical study of BRTX-100, targeting chronic lower back pain. BioRestorative aims to strengthen its market position in stem cell therapies.
BioRestorative Therapies, Inc. (OTC: BRTX) announced a notice of allowance from the U.S. Patent Office for a patent related to its ThermoStem® Program, granted on March 22, 2021. This patent involves methodologies for generating exosomes from brown adipose-derived stem cells, which may offer therapeutic benefits in treating various diseases. The exosome market is projected to reach $368 million by 2022. The CEO emphasized the importance of this patent for protecting their intellectual property and driving the company's growth strategy.
BioRestorative Therapies (OTC: BRTX) announced on March 22, 2021, that it received notices of allowance for three patent applications related to its ThermoStem® Program from the United States Patent Office and various international agencies. The patents cover a specific human brown adipose tissue-derived stem cell with potential therapeutic applications for degenerative and metabolic disorders. These allowances are expected to enhance the company's intellectual property and therapeutic pipeline, as stated by company executives.
BioRestorative Therapies, Inc. (OTC: BRTX) filed its Annual Report on Form 10-K for the year ended December 31, 2019, marking a crucial step towards regularizing its SEC filings following its Chapter 11 bankruptcy in 2020. The company received $3.8 million in financing as part of its reorganization and anticipates additional financing of $3.5 million as conditions allow. CEO Lance Alstodt stated that the filing reflects progress in operational efficiency and access to capital markets. The firm plans to file its 2020 quarterly and annual reports soon, aiming to update stakeholders on advancements in its stem cell therapy programs.